Background: Percutaneous left atrial appendage occlusion (LAAO), alternative to oral anticoagulation (OAC), currently faces non-standardized bleeding data and imprecise borderline ischemic signals within the direct oral anticoagulant (DOAC) era. Objective: This study applied a pragmatic framework to evaluate the comparative efficacy and safety of LAAO versus OAC in a DOAC-predominant setting. Methods: PubMed, Embase, and Cochrane Library were searched for randomized controlled trials comparing LAAO with OAC, restricted to a DOAC-predominant comparator. Risk ratios (RR) with 95% confidence intervals (CI) were calculated via a Mantel-Haenszel random-effects model. Results: Four trials comprising 5,890 patients were included (96.4% of controls assigned to DOACs). Overall stroke (RR 1.18, 95% CI 0.87–1.60; p=0.28), systemic embolism (RR 1.09, 95% CI 0.29–4.07; p=0.89), major bleeding (RR 0.98, 95% CI 0.81–1.19; p=0.84), hemorrhagic stroke (RR 0.82, 95% CI 0.45–1.51; p=0.53), and all-cause mortality (RR 1.00, 95% CI 0.85–1.17; p=0.98) did not differ significantly. Ischemic stroke presented a persistent numerical asymmetry favoring OAC that approached statistical significance (RR 1.36, 95% CI 0.99–1.89; p=0.06). Conversely, within available protocol-defined datasets, LAAO significantly reduced nonprocedural clinically relevant bleeding (RR 0.50, 95% CI 0.42–0.59; p<0.01). Conclusions: In a pragmatic analysis of the DOAC era, randomized data show statistical equivalence for individual hard clinical endpoints, alongside a persistent numerical asymmetry for ischemic stroke. The reduction in nonprocedural clinically relevant bleeding is driven by the attenuation of late non-major events. Current evidence remains non-definitive, warranting shared clinical decision-making to balance individual thromboembolic risks against long-term bleeding susceptibility.